OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Andikyan on the Rationale of Using HIPEC in Ovarian Cancer

February 10th 2023

Vaagn Andikyan, MD, discusses the utilization of hyperthermic intraperitoneal chemotherapy in patients with stage III epithelial ovarian cancer.

Dr. Perez Perez on Results From a Retrospective Study of Polatuzumab Regimens in R/R LBCL

February 10th 2023

Ariel Perez Perez, MD, discusses key results and clinical implications from a retrospective study of polatuzumab-vedotin plus rituximab with or without bendamustine in relapsed/refractory large B-cell lymphomas.

Dr. Kumar on Immunotherapy Combinations in RCC

February 10th 2023

Rohit Kumar, MD, discusses the benefits of combining immunotherapy agents with each other or with TKIs in patients with renal cell carcinoma and the unmet needs that remain for patients with RCC who do not respond to immunotherapy.

Dr. Singh on Treatment Updates in Urothelial Carcinoma

February 10th 2023

Vikas Kumar Singh, MD, discusses findings from the phase 3 GETUG-AFU V05 VESPER (NCT01812369) and JAVELIN Bladder 100 (NCT02603432) trials in patients with bladder cancer.

Dr. Ravi on Ongoing Investigation of PSMA-targeted Therapies in mCRPC

February 9th 2023

Praful K. Ravi, MB, BChir, MRCP, discusses ongoing and future clinical trials investigating the use of prostate-specific membrane antigen-targeted therapies in metastatic castration-resistant prostate cancer.

Dr. Kundranda on the Sequencing of Second-Line Therapies in HCC

February 9th 2023

Madappa Kundranda, MD, PhD, discusses the sequencing of second-line therapies in hepatocellular carcinoma.

Dr. Bidard on the FDA Approval of Elacestrant in ER+/HER2– Metastatic Breast Cancer

February 8th 2023

François-Clément Bidard, MD PhD, discusses the significance of the FDA approval of elacestrant in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer and key efficacy and safety data from the phase 3 EMERALD trial.

Dr. Choudhury on the Potential Benefit of PARP Inhibitor Use in mCRPC

February 8th 2023

Atish D. Choudhury, MD, PhD, discusses key biomarkers that may assist in the prediction of PARP inhibitor benefit in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Rhee on the Benefit of Zanubrutinib Vs Ibrutinib in R/R CLL

February 8th 2023

June-Wha Rhee, MD, discusses the benefit of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia, as well as the incidence of cardiac disorders associated with the BTK inhibitors.

Dr. Fallon on Supportive Care Considerations in R/R Multiple Myeloma

February 8th 2023

Michael J. Fallon, MD, discusses supportive care considerations for patients with relapsed/refractory multiple myeloma.

Dr. Wang on Ongoing Clinical Trials in BPDCN

February 8th 2023

Eunice Wang, MD, discusses ongoing clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm.

Dr. Bardia on the FDA Approval of Sacituzumab Govitecan in HR+/HER2– Metastatic Breast Cancer

February 8th 2023

Aditya Bardia, MD, MPH, discusses the significance of the FDA approval of sacituzumab govitecan in patients with pretreated hormone receptor–positive, HER2-negative metastatic breast cancer and key data from the phase 3 TROPiCS-02 trial.

Dr. Kumar on the Future of Triplet Regimens in Metastatic RCC

February 7th 2023

Rohit Kumar, MD, discusses the current and future uses of triplet combinations in metastatic renal cell carcinoma.

Dr. Carlo-Stella on the Investigation of RG6234 in R/R Multiple Myeloma

February 7th 2023

Carmelo Carlo-Stella, MD, PhD, discusses the evaluation of subcutaneous and intravenous RG6234 in relapsed/refractory multiple myeloma.

Dr. Chmielowski on the Current Treatment Landscape of Metastatic Melanoma

February 7th 2023

Bartosz Chmielowski, MD, discusses the current treatment landscape of metastatic melanoma.

Dr. Falkson on the Use of Sacituzumab Govitecan in HR+/HER2- Breast Cancer

February 7th 2023

Carla Falkson, MD, MBChB, MMed, discusses the use of the antibody-drug conjugate sacituzumab govitecan-hziy in hormone receptor–positive, HER2-negative breast cancer.

Dr. Liu on the Use of MET-targeted Agents in EGFR-mutant NSCLC

February 7th 2023

Stephen V. Liu, MD, discusses the future of MET-targeted agents in non–small cell lung cancer based on the FDA breakthrough designation for telisotuzumab vedotin.

Dr. Berg the Promise of Key Updates in Urothelial Cancer

February 7th 2023

Stephanie A. Berg, DO, discusses the promise of key updates in urothelial cancer, as well as highlights how these updates continue to affect treatment decisions for patients.

Dr. Mascarenhas on the Evolution of JAK Inhibitors in Myelofibrosis

February 7th 2023

John O. Mascarenhas, MD, discusses evolution of JAK inhibitors in the treatment landscape of myelofibrosis.

Dr. Siegel on the Importance of Investigating Ide-cel in Multiple Myeloma

February 7th 2023

David Siegel, MD, PhD, discusses the importance of investigating idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.